株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮頸癌の治療と診断

Therapies and Diagnostics for Cervical Cancer

発行 BCC Research 商品コード 279090
出版日 ページ情報 英文 211 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
子宮頸癌の治療と診断 Therapies and Diagnostics for Cervical Cancer
出版日: 2013年08月22日 ページ情報: 英文 211 Pages
概要

当レポートでは、世界の子宮頸癌診断・治療市場について調査し、市場の概要、実績データ・推計・CAGR予測を含めた世界の市場動向の分析、予防薬、スクリーニング・診断、手術、放射線治療および薬物治療別の市場分析、認可薬の概説、特許情勢の分析および主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 癌の主要タイプと死亡率
  • 癌:主要統計
  • 予防戦略
  • 現在のスクリーニング手法
  • 非伝染性疾病の行動計画
  • 歴史
  • 子宮頸癌の症状
  • 進行子宮頸癌の症状
  • 子宮頸癌の診断
  • 子宮頸癌のリスク因子
  • 子宮頸癌のステージ

第4章 子宮頸癌:生物学

  • ヒト・パピローマウィルス(HPV):種類
  • 浸潤子宮頸癌の組織学的なサブタイプ
  • 頸部で実際に発生する非悪性腫瘍
    • 子宮頸癌予防の新しいバイオマーカー
    • その他のバイオマーカー
    • バイオマーカーと将来

第5章 スクリーニング

  • スクリーニングの重要性
  • 子宮頸癌スクリーニングガイドライン
  • 子宮頸癌診断
  • 結論

第6章 子宮頸癌治療

  • 臨床ステージ・予後
  • 治療
  • リスク因子
  • スクリーニングプログラム
  • 細胞検査
  • 子宮頸癌の治療戦略
  • 子宮頸癌の概要
  • 新規・有望な治療法
  • 治験中の薬剤

第7章 子宮頸癌の発生率

  • 世界の癌概要
  • 一般的な癌
  • 将来の動向
  • 世界の子宮頸癌発生率
  • 近年の飛躍的進歩
  • 子宮頸癌の難しい時期
  • 予防戦略
  • スクリーニング・治療アプローチ
  • 結論

第8章 子宮頸癌診断市場

  • 子宮頸癌スクリーニング
  • 子宮頸癌診断検査市場
    • 子宮頸癌
    • PAPテスト:有益か否か?
    • 世界の膣鏡診検査市場
    • 子宮頸管内掻爬術(ECC)処置市場
    • HPV検査
    • 現在のHPV向け分子診断検査
    • 新しいアプローチ:メッセンジャーRNA(MRNA)ベースのE6/E7検出の機会
    • 新しいデバイス

第9章 子宮頸癌予防薬市場

  • 子宮頸癌ワクチン
  • 結論

第10章 治療市場

  • 子宮頸癌治療
  • 癌治療市場

第11章 特許情勢

  • 世界的な特許失効の影響

第12章 主要企業のプロファイル

  • ABBOTT LABORATORIES
  • ADVAXIS
  • ASTRAZENECA
  • BECTON, DICKENSON AND CO.
  • BRISTOL-MYERS SQUIBB
  • DIGENE CORP.
  • DENDREON CORP.
  • FEMASYS
  • GLAXOSMITHKLINE
  • HOLOGIC 208
  • ISA PHARMACEUTICALS
  • JOHNSON & JOHNSON
  • MERCK
  • ONCOHEALTH CORP.
  • PFIZER
  • QUEST DIAGNOSTICS
  • QIAGEN
  • ROCHE DIAGNOSTICS
  • SANOFI
  • TAJ PHARMACEUTICALS
  • TEVA PHARMACEUTICAL INDUSTRIES
  • TROVAGENE
  • ZILICO LTD.

第13章 参考資料

図表

目次
Product Code: HLC141A

This report provides:

  • An overview of the global market for cervical cancer diagnostics and therapies.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • A breakdown of the markets by prophylactics, screening and diagnostics, surgery, radiation therapy, and drug therapy.
  • Discussion of cervical cancer biology.
  • Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
  • Evaluation of the patent landscape.
  • Comprehensive profiles of key companies.

STUDY GOALS AND OBJECTIVES

This report provides an overview of the current and potential global market for cervical cancer, including treatments and screening and testing technologies. The report provides comprehensive information on cervical cancer, highlighting treatment guidelines. It identifies and analyzes the key trends driving the global cervical cancer therapeutics market. The key objective is to present a comprehensive analysis of current cervical cancer-related technologies and the utilization of various therapeutic, prophylactic, screening, and diagnostic modalities. The report's focus is on cervical disorders, current treatment strategies and drugs, chemotherapy, and other treatment modalities and testing and screening methods. Important trends in the field, research, new developments, and sales forecasts by treatment and screening categories from 2012 through 2018 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and health care policies, demographics, and other factors that directly affect the cervical cancer market.

The report also focuses on the treatment usage patterns in the global cervical cancer therapeutics market, the competitive landscape and emerging players, and pipeline products. It also details opportunities for future players.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information regarding prophylactics, screening, testing, and treatment options for cervical disorders and cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of cervical disorders and related cancers.

This BCC market research report will increase the awareness of current and emerging drugs and technologies for cervical cancers, including prophylactics, therapeutics, chemotherapy, and surgical therapy.

SCOPE OF THE STUDY

The scope of this study includes testing, prophylactics vaccines, screening tests and methods, and therapeutics markets for cervical cancers. The report also discusses current technologies, new technologies, cervical cancer incidence, and market projections and market share, along with latest trends and new developments.

A comprehensive and exhaustive search of the literature was conducted on cervical cancer and disorders; products; global incidence; and drug developments. Secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis were also completed. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academic institutions and technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as pharmaceutical and biotechnical companies and research institutes. Data were gathered from various industry sources. BCC spoke with officials within the industry and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases using key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs involving target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology, and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY
  • SUMMARY TABLE: CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • TABLE 1: MAIN TYPES OF CANCER AND MORTALITY
  • FIGURE 1: MAIN TYPES OF CANCER AND MORTALITY
  • TABLE 2: CANCER: KEY FACTS
  • TABLE 3: PREVENTION STRATEGIES
  • EARLY DETECTION
  • EARLY DIAGNOSIS
  • SCREENING
    • TABLE 4: CURRENT SCREENING METHODS
  • CANCER TREATMENT
    • TABLE 5: NONCOMMUNICABLE DISEASES ACTION PLAN
  • CERVICAL CANCER
    • TABLE 6: HISTORY
  • CERVICAL CANCER RESEARCH AND TREATMENT
  • SENTINEL LYMPH NODE BIOPSY
  • HUMAN PAPILLOMAVIRUS (HPV) VACCINES
  • TARGETED THERAPY
  • HYPERTHERMIA
  • DRUG TREATMENT OF PRECANCERS
  • SYMPTOMS
    • TABLE 7: CERVICAL CANCER SYMPTOMS
    • TABLE 8: ADVANCED CERVICAL CANCER SYMPTOMS
  • DIAGNOSIS
    • TABLE 9: DIAGNOSIS OF CERVICAL CANCER
    • TABLE 10: RISK FACTORS FOR CERVICAL CANCER
  • TREATMENT
    • TABLE 11: CERVICAL CANCER STAGING
  • PROGNOSIS

CHAPTER 4 - CERVICAL CANCER: BIOLOGY

  • CERVIX
  • CAUSES
  • HUMAN PAPILLOMAVIRUS
    • TABLE 12: HUMAN PAPILLOMAVIRUS: TYPES
  • SYMPTOMS OF GENITAL WARTS
  • HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS AND TRANSMISSION
  • E6/E7 PROTEINS
  • VACCINES
  • TREATMENT OF GENITAL WARTS
  • CANCER SUBTYPES
    • TABLE 13: HISTOLOGIC SUBTYPES OF INVASIVE CERVICAL CARCINOMA
    • TABLE 14: NON-CARCINOMA MALIGNANCIES THAT CAN RARELY OCCUR IN THE CERVIX
  • NOVEL BIOMARKERS IN CERVICAL CANCER PREVENTION
  • E6/E7 MESSENGER RNA (MRNA) DETECTION
  • P16INK4A
  • OTHER BIOMARKERS
  • EPIGENETIC MARKERS: DNA METHYLATION
  • VIRAL METHYLATION
  • CHROMOSOMAL ABNORMALITIES
  • MICRORNAS (MIRNAS)
  • BIOMARKERS AND THE FUTURE

CHAPTER 5 - SCREENING

  • WHY SCREENING IS CRITICAL
  • CERVICAL CANCER SCREENING GUIDELINES
  • VACCINATION
  • CERVICAL CANCER DIAGNOSIS
  • EXAMINATION
  • COMPUTED TOMOGRAPHY
  • BIOPSY
  • PRECANCEROUS LESIONS
  • CLINICAL STAGING
    • TABLE 15: THE MAJOR CATEGORIES OF THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) CLASSIFICATION
  • LYMPH NODE EVALUATION
    • TABLE 16: THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) STAGES
  • Additional Staging
  • LIMITATIONS OF TECHNIQUES
  • CERVICAL CANCER SCREENING
    • TABLE 17: TWO SCREENING TESTS THAT HELP PREVENT CERVICAL CANCER OR DETECT IT EARLY
  • PAP TEST
    • TABLE 18: TYPES OF SCREENING FOR CERVICAL CANCER
    • TABLE 19: PAP TEST INDICATIONS
    • TABLE 20: BETHESDA SYSTEM
  • Pap Tests: Issues
  • HUMAN PAPILLOMAVIRUS (HPV) TEST
  • Tests and Challenges
  • Procedure and Current Status
  • FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS
    • TABLE 21: FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS
  • Digene Hybrid Capture 2 (HC2) High-Risk HPV DNA Test
  • Cervista HPV HR and Genfind DNA Extraction Kit
  • Cervista HPV 16/18
  • cobas Human Papillomavirus (HPV) Test
  • APTIMA Human Papillomavirus (HPV) Assay
  • DIAGNOSTIC TESTS
  • Colposcopy
  • Cervical Biopsies
  • Colposcopic Biopsy
  • Endocervical Curettage (Endocervical Scraping)
  • Cone Biopsy
  • CYSTOSCOPY, PROCTOSCOPY, AND EXAMINATION UNDER ANESTHESIA
  • IMAGING STUDIES
  • CERVICAL CANCER SCREENING GUIDELINES
    • TABLE 22: CERVICAL CANCER SCREENING
  • CERVICAL CANCER SCREENING
  • Total Hysterectomy and Pap Tests: Issues
    • TABLE 23: THE ACS-ASCCP-ASCP RECOMMENDATIONS: CHANGES FROM THE PREVIOUS ACS GUIDELINES
  • TYPES OF GYNECOLOGIC TUMOR MARKERS
    • TABLE 24: IMPORTANT GYNECOLOGIC TUMOR MARKERS
    • TABLE 25: OTHER POTENTIAL GYNECOLOGIC TUMOR MARKERS
  • CLINICAL USEFULNESS OF TUMOR MARKERS
  • CONCLUSION

CHAPTER 6 - THE TREATMENT OF CERVICAL CANCER

  • CLINICAL STAGES AND PROGNOSIS
  • TREATMENT
  • RISK FACTORS
  • SCREENING PROGRAMS
  • CYTOLOGIC TESTS
  • CONVENTIONAL CYTOLOGY
  • CLASSIFICATION SYSTEM
    • TABLE 26: THE BETHESDA SYSTEM
  • CERVICAL CANCER TREATMENT STRATEGIES
  • CERVICAL CANCER OVERVIEW
  • STAGE-BASED THERAPY
  • Stage 0 Cancer
  • Stage IA1 Cancer
  • Stage IA2, IB, or IIA Cancer
  • Stage IIB, III, or IVA Cancer
  • Stage IVB and Recurrent Cancer
  • COMPLICATIONS OF THERAPY
  • Radiation-Related Complications
  • Problems Due to Surgeries
  • THERAPEUTIC STRATEGY
    • TABLE 27: DRUGS APPROVED TO TREAT CERVICAL CANCER
  • Chemotherapy
    • TABLE 28: COMMON CHEMOTHERAPY MEDICINES USED TO TREAT CERVICAL CANCER
  • Cisplatin
  • Ifosfamide (Ifex)
  • Fluorouracil (Adrucil)
  • Paclitaxel (Taxol)
  • Topotecan (Hycamtin)
  • Docetaxel
  • Gemcitabine
  • Vaccines: Inactivated, Viral
  • Human Papillomavirus Vaccine, Quadrivalent (Gardasil)
  • Human Papillomavirus Vaccine, Bivalent (Cervarix)
  • NEW AND PROMISING THERAPIES
  • DRUGS IN CLINICAL TRIALS
  • Ixabepilone
  • ADXS11-001
  • ISA101 Vaccine
  • Veliparib
  • Carcinoembryonic Antigen (CEA)
  • Olaparib

CHAPTER 7 - CERVICAL CANCER INCIDENCE

  • CANCER WORLDWIDE-THE GLOBAL PICTURE
    • TABLE 29: POPULATION MEASURES AND CANCER INCIDENCE AND MORTALITY IN REGIONS OF THE WORLD, ESTIMATES 2008-2010
  • COMMON CANCERS
    • TABLE 30: TOTAL NUMBER AND PERCENTAGES OF ALL CANCER DEATHS, WORLDWIDE, 2008
  • FUTURE TRENDS
    • TABLE 31: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED CANCER INCIDENCE RATES PER 100,000 POPULATION, U.K., 2007-2030
  • GLOBAL INCIDENCE OF CERVICAL CANCER
    • TABLE 32: POPULATION ATTRIBUTABLE FRACTION (%)
    • TABLE 33: CERVICAL CANCER: GLOBAL INCIDENCE, 2008
    • TABLE 34: GLOBAL CERVICAL CANCER: MORTALITY 2008 AND 2030*
  • RECENT BREAKTHROUGHS
    • TABLE 35: WORLDWIDE PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) IN WOMEN WITH CERVICAL CANCER
  • CERVICAL CANCER THOUGH TIME
    • TABLE 36: CERVICAL CANCER BY CONTINENTS, 2008 ESTIMATES
    • TABLE 37: CERVICAL CANCER WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION, FEMALES IN WORLD REGIONS, 2008 ESTIMATES
    • TABLE 38: CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)
    • FIGURE 2: CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2
  • (THOUSANDS)
    • TABLE 39: WORLDWIDE BURDEN OF CERVICAL CANCER BY AREA, 2008
    • TABLE 40: CHANGING TRENDS IN CANCER-SPECIFIC AGE-ADJUSTED INCIDENCE (%)
  • PREVENTION STRATEGIES
  • CERVICAL CANCER AND THE U.S.
    • TABLE 41: U.S.: ESTIMATED NEW CASES AND DEATHS FROM CERVICAL (UTERINE CERVIX) CANCER, 2012 AND 2013
  • INCIDENCE AND MORTALITY
    • TABLE 42: U.S.: INCIDENCE RATES BY RACE, 2005-2009
  • U.S. Cervical Cancer Mortality
    • TABLE 43: U.S.: DEATH RATES BY RACE, 2005-2009
  • Survival and Stage
    • TABLE 44: STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, ALL RACES, FEMALES, 2002-2008
    • TABLE 45: FIVE-YEAR OBSERVED SURVIVAL RATE
  • European Union
    • TABLE 46: CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES
    • FIGURE 3: CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES
  • U.K.
    • TABLE 47: NUMBER OF NEW CASES AND CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2009
    • TABLE 48 CERVICAL CANCER: AVERAGE NUMBER OF NEW CASES PER YEAR AND AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2007-2009
    • TABLE 49: CERVICAL CANCER: PERCENTAGE CHANGE IN AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2008-2009
    • TABLE 50: CERVICAL CANCER: ONE-YEAR, FIVE-YEAR, AND 10-YEAR CANCER PREVALENCE AMONG FEMALES IN U.K., DECEMBER 31, 2006
    • TABLE 51: NUMBER OF NEW CASES IN U.K., 2009 AND 2010
    • TABLE 52: U.K.: THE 10 MOST COMMONLY DIAGNOSED CANCERS IN FEMALES IN 1984, 2007, AND 2030
    • TABLE 53: CERVICAL CANCER: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION IN U.K., 2010 AND 2030
    • TABLE 54: U.K.: THE 10 MOST COMMON CAUSES OF CANCER DEATH IN FEMALES IN 1990, 2010, AND 2030
  • India
  • China
  • Africa
    • TABLE 55: KEY STATISTICS IN AFRICA AND ITS REGIONS, 2008
    • TABLE 56: HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN THE GENERAL POPULATION, 2008
    • TABLE 57: AFRICA: PREVALENCE HPV 16 AND/OR HPV 18 AMONG WOMEN WITH THE FOLLOWING CHARACTERISTICS
    • TABLE 58: INCIDENCE OF CERVICAL CANCER IN AFRICA BY REGION, 2008
    • TABLE 59: MORTALITY OF CERVICAL CANCER IN AFRICA BY REGION, 2008
    • TABLE 60: AGE-STANDARDIZED INCIDENCE RATES OF CERVICAL CANCER IN AFRICA, 2008
    • TABLE 61: AGE-STANDARDIZED MORTALITY RATES OF CERVICAL CANCER IN AFRICA, 2008
  • SCREENING AND TREATMENT APPROACHES
  • SAUDI ARABIA
  • NIGERIA
  • KENYA
  • GAMBIA
  • CANADA
  • GERMANY
    • TABLE 62: INCIDENCE OF CERVICAL CANCER IN GERMANY, WESTERN EUROPE, AND THE WORLD, 2008 (RATES PER 100,000 WOMEN PER YEAR)
    • TABLE 63: KEY STATISTICS ON GERMANY, 2010-2025
  • AUSTRALIA
    • TABLE 64: AUSTRALIA: PROJECTED COMMON CANCERS IN FEMALES, 2020
    • TABLE 65: AUSTRALIA: PROJECTED NUMBER OF NEW CERVICAL CANCER CASES AND AGE-STANDARDIZED RATES AMONG FEMALES WITH 95% PREDICTION INTERVALS, 2011-2020
    • TABLE 66: AUSTRALIA: PROJECTED CERVICAL CANCER STATISTICS, 2020
  • HONG KONG
  • CONCLUSION

CHAPTER 8 - CERVICAL CANCER DIAGNOSTICS MARKET

  • TABLE 67: WOMEN UNDERGOING CERVICAL CANCER SCREENING
  • CERVICAL CANCER SCREENING
  • CERVICAL CANCER TESTING GUIDELINES
  • CERVICAL CANCER DIAGNOSTIC TESTS MARKET
    • TABLE 68: WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, THROUGH 2018 ($ MILLIONS)
    • FIGURE 4: WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, 2012-2018 ($ MILLIONS)
  • MARKET DRIVERS
    • TABLE 69: MARKET DRIVERS
    • TABLE 70: KEY PLAYERS
  • RESTRAINTS
  • Lack of Appropriate Health Care Infrastructure in Underdeveloped and Developing Countries
  • HPV VACCINATION
  • Available Vaccines
  • WHO Recommends the Vaccine for Girls Between the Ages of
  • and 13
  • WHO Does Not Recommend the Vaccine for Boys
  • CERVICAL CANCER DIAGNOSTIC TESTS MARKET BY TEST TYPES
  • Pap Smear Test
    • TABLE 71: GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 5: GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
    • TABLE 72: NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (MILLIONS)
  • Pap Tests: U.S.
    • TABLE 73: U.S.: PERCENT OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 (%)
    • TABLE 74: U.S.: PERCENT OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010 (%)
    • TABLE 75: PAP TESTS ORDERED OR PROVIDED IN U.S., 2010
    • TABLE 76: PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT DEPARTMENT VISITS IN U.S., 2010
  • Latest Technology
  • Canadian Market
  • Ontario Guidelines
  • Cervical Cancer and India
  • PAP TESTS: BENEFIT OR NOT?
    • TABLE 77: ABNORMALITIES OF THE CERVIX
  • GLOBAL COLPOSCOPY TESTS MARKET
    • TABLE 78: WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)
    • FIGURE 6: WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)
    • TABLE 79: CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 7: CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
    • TABLE 80: CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., THROUGH 2018 ($ MILLIONS)
    • FIGURE 8: CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., 2012-2018 ($ MILLIONS)
  • Biopsy
  • Types of Cervical Biopsies
    • TABLE 81: TYPES OF CERVICAL BIOPSIES
  • ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET
    • TABLE 82: WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 9: WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • Femasys
  • Liquid-Based Cytology
  • HPV TESTING
    • TABLE 83: WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 10: WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • TABLE 84: KEY PLAYERS
  • CURRENT MOLECULAR DIAGNOSTIC TESTS FOR HUMAN PAPILLOMAVIRUS (HPV)
  • A NEW APPROACH: MESSENGER RNA (MRNA)-BASED DETECTION OF E6/E7 ONCOPROTEINS
  • bioMerieux's Test
  • Roche
  • Innovative Cervical Screening Application Launches in the U.K., and Ireland
  • Quest Diagnostics
  • OncoHealth
  • QIAGEN/Digene
  • Trovagene
  • Becton, Dickinson and Co.: Human Papillomavirus (HPV) Testing and Issues
  • NEW DEVICES
  • Zilico
  • LUMA Cervical Imaging System

CHAPTER 9 - CERVICAL CANCER PROPHYLACTICS MARKET

  • CERVICAL CANCER VACCINES
    • TABLE 85: VACCINES FOR PREVENTION OF CERVICAL CANCER
  • COMPETITION
  • CERVICAL CANCER PROPHYLACTICS MARKET
  • Preventative Vaccines
    • TABLE 86: GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 11: GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • Vaccine Market: Leaders
    • TABLE 87: KEY COMPANIES: CERVICAL VACCINE MARKET REVENUES AND FORECAST, 2011 AND 2018 ($ MILLIONS)
  • GLOBAL CANCER VACCINES MARKET
    • TABLE 88: GLOBAL VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 89: KEY COMPANIES
  • CANCER VACCINE MARKET: U.S.
    • TABLE 90: U.S. VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • PROPHYLACTIC VACCINES
  • PROPHYLACTIC CANCER VACCINES MARKET
  • Cervarix
    • TABLE 91: GLOBAL CERVARIX SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 12: GLOBAL CERVARIX SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • Gardasil
    • TABLE 92: GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS)
    • FIGURE 13: GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS)
  • NEW PRODUCTS
  • VS03
    • TABLE 93: V503 SALES AND FORECAST, 2013 AND 2018 ($ MILLIONS)
  • LATEST DEVELOPMENTS
  • U.K. to Drop Cervarix
  • Cancer Vaccines in Poor Nations
  • CONCLUSIONS

CHAPTER 10 - THERAPEUTIC MARKET

  • TABLE 94: CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS)
  • FIGURE 14: CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS)
  • TREATMENT OF CERVICAL CANCER
    • TABLE 95: TYPES OF SURGERY FOR EARLY CERVICAL CANCER
  • CHEMOTHERAPY MARKET
  • CANCER TREATMENT MARKET
  • CANCER THERAPY
    • TABLE 96: MAJOR PLAYERS
  • Cancer Costs in the U.S.
    • TABLE 97: KEY FACTS: CANCER IN U.S., 2020
    • TABLE 98: U.S.: CERVICAL CANCER PREVALENCE ESTIMATES FOR 2010 AND 2020 (THOUSANDS)
    • TABLE 99: CERVICAL CANCER: CANCER PREVALENCE IN U.S.
    • TABLE 100: CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS)
  • CYTOTOXIC THERAPIES MARKET
    • TABLE 101: CYTOTOXIC THERAPIES MARKET INDICATIONS
    • TABLE 102: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
    • FIGURE 15: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
    • TABLE 103: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
    • FIGURE 16: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 104: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
    • FIGURE 17: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 105: JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
    • FIGURE 18: JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 ($ MILLIONS)
  • CERVICAL CHEMOTHERAPY MARKET
    • TABLE 106: CERVICAL CANCER CHEMOTHERAPY MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 19: CERVICAL CANCER MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS)
    • TABLE 107: CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 20: CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • CHEMOTHERAPY AND DRAWBACKS
  • DRUGS USED IN CHEMOTHERAPY
    • TABLE 108: DRUGS APPROVED TO TREAT CERVICAL CANCER
  • Paclitaxel
    • TABLE 109: SALES OF KEY DRUGS FOR CERVICAL CANCER, 2010 ($ MILLIONS)
  • Carboplatin
    • TABLE 110: CARBOPLATIN SALES, 2010-2012 ($ MILLIONS)
  • Taxotere/Docetaxel
    • TABLE 111: TAXOTERE GLOBAL SALES AND FORECAST, 2010-2012 ($ MILLIONS)
  • Gemzar
    • TABLE 112: GEMZAR REVENUE, 2010 AND 2011 ($ MILLIONS)
  • Future for Gemcitabine as a Drug
  • Cisplatin
  • Hycamtin
    • TABLE 113: HYCAMTIN SALES, 2010-2012 ($ MILLIONS)
  • Bleomycin
  • OTHER TREATMENT DRUGS
  • Avastin
    • TABLE 114: AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • CANCER IMMUNOTHERAPY
  • TREATMENT STRATEGIES
    • TABLE 115: CERVICAL CANCER: TREATMENT OPTIONS, 1999-2008 (%)
  • TREATMENT PROCEDURE COST ESTIMATES
  • CERVICAL CANCER SURGERY
    • TABLE 116: CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 21: CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • COSTS OF CERVICAL CANCER SURGERY
    • TABLE 117: SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 22: SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • TABLE 118: HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 23: HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • RADIATION THERAPY FOR CERVICAL CANCER
  • Radiation Therapy and Cost Estimates
    • TABLE 119: CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 24: CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL-SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • TABLE 120: CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 25: CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • CONCLUSIONS
    • TABLE 121: KEY FACTS ABOUT CERVICAL CANCER

CHAPTER 11 - PATENT LANDSCAPE

  • TABLE 122: CERVICAL CANCER VACCINE PATENTS (%)
  • GLOBAL IMPACT OF PATENT EXPIRIES
  • PATENT LANDSCAPE
  • Hycamtin (Topotecan Hydrochloride)
  • Gemzar
    • TABLE 123: CERVICAL CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY
  • Doxil
  • Cisplatin
  • Avastin

CHAPTER 12 - SELECTED COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ADVAXIS
  • ASTRAZENECA
  • BECTON, DICKENSON AND CO.
  • BRISTOL-MYERS SQUIBB
  • DIGENE CORP.
  • DENDREON CORP.
  • FEMASYS
  • GLAXOSMITHKLINE
  • HOLOGIC
  • ISA PHARMACEUTICALS
  • JOHNSON & JOHNSON
  • MERCK
  • ONCOHEALTH CORP.
  • PFIZER
  • QUEST DIAGNOSTICS
  • QIAGEN
  • ROCHE DIAGNOSTICS
  • SANOFI
  • TAJ PHARMACEUTICALS
  • TEVA PHARMACEUTICAL INDUSTRIES
  • TROVAGENE
  • ZILICO LTD.

CHAPTER 13 - REFERENCES

LIST OF TABLES

  • SUMMARY TABLE: CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 ($ MILLIONS)
  • TABLE 1: MAIN TYPES OF CANCER AND MORTALITY
  • TABLE 2: CANCER: KEY FACTS
  • TABLE 3: PREVENTION STRATEGIES
  • TABLE 4: CURRENT SCREENING METHODS
  • TABLE 5: NONCOMMUNICABLE DISEASES ACTION PLAN
  • TABLE 6: HISTORY
  • TABLE 7: CERVICAL CANCER SYMPTOMS
  • TABLE 8: ADVANCED CERVICAL CANCER SYMPTOMS
  • TABLE 9: DIAGNOSIS OF CERVICAL CANCER
  • TABLE 10: RISK FACTORS FOR CERVICAL CANCER
  • TABLE 11: CERVICAL CANCER STAGING
  • TABLE 12: HUMAN PAPILLOMAVIRUS: TYPES
  • TABLE 13: HISTOLOGIC SUBTYPES OF INVASIVE CERVICAL CARCINOMA
  • TABLE 14: NON-CARCINOMA MALIGNANCIES THAT CAN RARELY OCCUR IN THE CERVIX
  • TABLE 15: THE MAJOR CATEGORIES OF THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) CLASSIFICATION
  • TABLE 16: THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) STAGES
  • TABLE 17: TWO SCREENING TESTS THAT HELP PREVENT CERVICAL CANCER OR DETECT IT EARLY
  • TABLE 18: TYPES OF SCREENING FOR CERVICAL CANCER
  • TABLE 19: PAP TEST INDICATIONS
  • TABLE 20: BETHESDA SYSTEM
  • TABLE 21: FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS
  • TABLE 22: CERVICAL CANCER SCREENING
  • TABLE 23: THE ACS-ASCCP-ASCP RECOMMENDATIONS: CHANGES FROM THE PREVIOUS ACS GUIDELINES
  • TABLE 24: IMPORTANT GYNECOLOGIC TUMOR MARKERS
  • TABLE 25: OTHER POTENTIAL GYNECOLOGIC TUMOR MARKERS
  • TABLE 26: THE BETHESDA SYSTEM
  • TABLE 27: DRUGS APPROVED TO TREAT CERVICAL CANCER
  • TABLE 28: COMMON CHEMOTHERAPY MEDICINES USED TO TREAT CERVICAL CANCER
  • TABLE 29: POPULATION MEASURES AND CANCER INCIDENCE AND MORTALITY IN REGIONS OF THE WORLD, ESTIMATES 2008-2010
  • TABLE 30: TOTAL NUMBER AND PERCENTAGES OF ALL CANCER DEATHS, WORLDWIDE, 2008
  • TABLE 31: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED CANCER INCIDENCE RATES PER 100,000 POPULATION, U.K., 2007-2030
  • TABLE 32: POPULATION ATTRIBUTABLE FRACTION (%)
  • TABLE 33: CERVICAL CANCER: GLOBAL INCIDENCE, 2008
  • TABLE 34: GLOBAL CERVICAL CANCER: MORTALITY 2008 AND 2030*
  • TABLE 35: WORLDWIDE PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) IN WOMEN WITH CERVICAL CANCER
  • TABLE 36: CERVICAL CANCER BY CONTINENTS, 2008 ESTIMATES
  • TABLE 37: CERVICAL CANCER WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION, FEMALES IN WORLD REGIONS, 2008 ESTIMATES
  • TABLE 38: CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)
  • TABLE 39: WORLDWIDE BURDEN OF CERVICAL CANCER BY AREA, 2008
  • TABLE 40: CHANGING TRENDS IN CANCER-SPECIFIC AGE-ADJUSTED INCIDENCE (%)
  • TABLE 41: U.S.: ESTIMATED NEW CASES AND DEATHS FROM CERVICAL (UTERINE CERVIX) CANCER, 2012 AND 2013
  • TABLE 42: U.S.: INCIDENCE RATES BY RACE, 2005-2009
  • TABLE 43: U.S.: DEATH RATES BY RACE, 2005-2009
  • TABLE 44: STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, ALL RACES, FEMALES, 2002-2008
  • TABLE 45: FIVE-YEAR OBSERVED SURVIVAL RATE
  • TABLE 46: CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES
  • TABLE 47: NUMBER OF NEW CASES AND CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2009
  • TABLE 48: CERVICAL CANCER: AVERAGE NUMBER OF NEW CASES PER YEAR AND AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2007-2009
  • TABLE 49: CERVICAL CANCER: PERCENTAGE CHANGE IN AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2008-2009
  • TABLE 50: CERVICAL CANCER: ONE-YEAR, FIVE-YEAR, AND 10-YEAR CANCER PREVALENCE AMONG FEMALES IN U.K., DECEMBER 31, 2006
  • TABLE 51: NUMBER OF NEW CASES IN U.K., 2009 AND 2010
  • TABLE 52: U.K.: THE 10 MOST COMMONLY DIAGNOSED CANCERS IN FEMALES IN 1984, 2007, AND 2030
  • TABLE 53: CERVICAL CANCER: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION IN U.K., 2010 AND 2030
  • TABLE 54: U.K.: THE 10 MOST COMMON CAUSES OF CANCER DEATH IN FEMALES IN 1990, 2010, AND 2030
  • TABLE 55: KEY STATISTICS IN AFRICA AND ITS REGIONS, 2008
  • TABLE 56: HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN THE GENERAL POPULATION, 2008
  • TABLE 57: AFRICA: PREVALENCE HPV 16 AND/OR HPV 18 AMONG WOMEN WITH THE FOLLOWING CHARACTERISTICS
  • TABLE 58: INCIDENCE OF CERVICAL CANCER IN AFRICA BY REGION, 2008
  • TABLE 59: MORTALITY OF CERVICAL CANCER IN AFRICA BY REGION, 2008
  • TABLE 60: AGE-STANDARDIZED INCIDENCE RATES OF CERVICAL CANCER IN AFRICA, 2008
  • TABLE 61: AGE-STANDARDIZED MORTALITY RATES OF CERVICAL CANCER IN AFRICA, 2008
  • TABLE 62: INCIDENCE OF CERVICAL CANCER IN GERMANY, WESTERN EUROPE, AND THE WORLD, 2008 (RATES PER 100,000 WOMEN PER YEAR)
  • TABLE 63: KEY STATISTICS ON GERMANY, 2010-2025
  • TABLE 64: AUSTRALIA: PROJECTED COMMON CANCERS IN FEMALES, 2020
  • TABLE 65: AUSTRALIA: PROJECTED NUMBER OF NEW CERVICAL CANCER CASES AND AGE-STANDARDIZED RATES AMONG FEMALES WITH 95% PREDICTION INTERVALS, 2011-2020
  • TABLE 66: AUSTRALIA: PROJECTED CERVICAL CANCER STATISTICS, 2020
  • TABLE 67: WOMEN UNDERGOING CERVICAL CANCER SCREENING
  • TABLE 68: WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 69: MARKET DRIVERS
  • TABLE 70: KEY PLAYERS
  • TABLE 71: GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 72: NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (MILLIONS)
  • TABLE 73: U.S.: PERCENT OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 (%)
  • TABLE 74: U.S.: PERCENT OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010 (%)
  • TABLE 75: PAP TESTS ORDERED OR PROVIDED IN U.S., 2010
  • TABLE 76: PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT DEPARTMENT VISITS IN U.S., 2010
  • TABLE 77: ABNORMALITIES OF THE CERVIX
  • TABLE 78: WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)
  • TABLE 79: CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 80: CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., THROUGH 2018 ($ MILLIONS)
  • TABLE 81: TYPES OF CERVICAL BIOPSIES
  • TABLE 82: WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 83: WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 84: KEY PLAYERS
  • TABLE 85: VACCINES FOR PREVENTION OF CERVICAL CANCER
  • TABLE 86: GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 87: KEY COMPANIES: CERVICAL VACCINE MARKET REVENUES AND FORECAST, 2011 AND 2018 ($ MILLIONS)
  • TABLE 88: GLOBAL VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 89: KEY COMPANIES
  • TABLE 90: U.S. VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 91: GLOBAL CERVARIX SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 92: GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS)
  • TABLE 93: V503 SALES AND FORECAST, 2013 AND 2018 ($ MILLIONS)
  • TABLE 94: CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS)
  • TABLE 95: TYPES OF SURGERY FOR EARLY CERVICAL CANCER
  • TABLE 96: MAJOR PLAYERS
  • TABLE 97: KEY FACTS: CANCER IN U.S., 2020
  • TABLE 98: U.S.: CERVICAL CANCER PREVALENCE ESTIMATES FOR 2010 AND 2020 (THOUSANDS)
  • TABLE 99: CERVICAL CANCER: CANCER PREVALENCE IN U.S.
  • TABLE 100: CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS)
  • TABLE 101: CYTOTOXIC THERAPIES MARKET INDICATIONS
  • TABLE 102: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
  • TABLE 103: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 104: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 105: JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 106: CERVICAL CANCER CHEMOTHERAPY MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS)
  • TABLE 107: CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 108: DRUGS APPROVED TO TREAT CERVICAL CANCER
  • TABLE 109: SALES OF KEY DRUGS FOR CERVICAL CANCER, 2010 ($ MILLIONS)
  • TABLE 110: CARBOPLATIN SALES, 2010-2012 ($ MILLIONS)
  • TABLE 111: TAXOTERE GLOBAL SALES AND FORECAST, 2010-2012 ($ MILLIONS)
  • TABLE 112: GEMZAR REVENUE, 2010 AND 2011 ($ MILLIONS)
  • TABLE 113: HYCAMTIN SALES, 2010-2012 ($ MILLIONS)
  • TABLE 114: AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 115: CERVICAL CANCER: TREATMENT OPTIONS, 1999-2008 (%)
  • TABLE 116: CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 117: SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 118: HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 119: CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 120: CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 121: KEY FACTS ABOUT CERVICAL CANCER
  • TABLE 122: CERVICAL CANCER VACCINE PATENTS (%)
  • TABLE 123: CERVICAL CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY

LIST OF FIGURES

  • SUMMARY FIGURE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 ($ MILLIONS)
  • FIGURE 1: MAIN TYPES OF CANCER AND MORTALITY
  • FIGURE 2: CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)
  • FIGURE 3: CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES
  • FIGURE 4: WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, 2012-2018 ($ MILLIONS)
  • FIGURE 5: GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 6: WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)
  • FIGURE 7: CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 8: CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., 2012-2018 ($ MILLIONS)
  • FIGURE 9: WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 10: WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 11: GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 12: GLOBAL CERVARIX SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 13: GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS)
  • FIGURE 14: CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS)
  • FIGURE 15: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
  • FIGURE 16: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 17: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 18: JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 ($ MILLIONS)
  • FIGURE 19: CERVICAL CANCER MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS)
  • FIGURE 20: CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 21: CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 22: SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 23: HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 24: CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL-SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • FIGURE 25: CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS)
Back to Top